Yashoda Super Specialty Kaushambi
The Subject Expert Committee of Drugs Controller General of India (DCGI) on Wednesday recommended Serum Institute’s indigenously developed quadrivalent human papillomavirus (qHPV) vaccine for cervical cancer patients.
“An expert panel of India’s central drug authority on Wednesday recommended granting of market authorisation to Serum Institute of India (SII) indigenously-developed India’s first Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer”, said a source.
The vaccine has been recommended for cervical cancer patients those above 9 years to 26 years of age for both male and female.According to the source, an application has also been sent to the National Technical Advisory Group on Immunisation (NTAGI).
The NTAGI may take the final decision on the HPV vaccine in the next meeting scheduled to be held on June 29.
Diarrhea remains one of the leading killers of children under five and the elderly, particularly…
Union Health Secretary Punya Salila Srivastava on Thursday said that healthcare is not only a…
Union Education and Health ministries are working on a proposal to switch the medical entrance…
In an effort to improve the patient experience, Ameera Shah-led Metropolis Healthcare Limited, India’s second-largest…